This site is intended for US Health Care Professionals only.
INDICATIONS: KENALOG-10 INJECTION
Intra-Articular or Soft Tissue Administration
KENALOG-10 Injection is indicated as adjunctive therapy for short-term administration in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
Intralesional Administration
KENALOG-10 is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. It may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).
INDICATIONS: KENALOG-40 AND KENALOG-80 INJECTION
Intra-Articular or Soft Tissue Administration
KENALOG-40 AND KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
Intramuscular Administration
When oral therapy is not feasible, KENALOG-40 AND KENALOG-80 are indicated for:
INDICATIONS: KENALOG-40 AND KENALOG-80 INJECTION
Intramuscular Administration (KENALOG-40 AND KENALOG-80) (cont)
INDICATIONS: KENALOG-40 AND KENALOG-80 INJECTION
Intramuscular Administration (KENALOG-40 AND KENALOG-80) (cont)
Click for additional indications
INDICATIONS: KENALOG-10 INJECTION
Intra-Articular or Soft Tissue Administration
KENALOG-10 Injection is indicated as adjunctive therapy for short-term administration in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
Intralesional Administration
KENALOG-10 is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. It may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).
INDICATIONS: KENALOG-40 AND KENALOG-80 INJECTION
Intra-Articular or Soft Tissue Administration
KENALOG-40 AND KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
Intramuscular Administration
When oral therapy is not feasible, KENALOG-40 AND KENALOG-80 are indicated for:
INDICATIONS: KENALOG-40 AND KENALOG-80 INJECTION
Intramuscular Administration (KENALOG-40 AND KENALOG-80) (cont)
INDICATIONS: KENALOG-40 AND KENALOG-80 INJECTION
Intramuscular Administration (KENALOG-40 AND KENALOG-80) (cont)
Click for additional indications
KENALOG-10 Injection may offer patients anti-inflammatory action across multiple disease states.1
Please see additional Important Safety Information below.
KENALOG-10 Injection may offer patients anti-inflammatory action across multiple disease states.1
For more information on the use of intralesional glucocorticoid injections such as KENALOG-10 Injection to manage psoriatic plaques that fail to respond to topical therapy,10-13 please see references published by the American Academy of Family Physicians,10 the American Board of Family Medicine,11 and the American Academy of Dermatology.12
From a BMS analysis of 14 published prospective randomized clinical trials or observational studies (N=1362), the most common adverse reactions (1-10%) with KENALOG-10 Injection in adults and pediatrics were: arthralgia (3.1%), infection (2.2%), headache (1.4%), and injection site reaction (1.1%).1
KENALOG Injection is not for use in neonates. Contains benzyl alcohol.
KENALOG is not for intravenous, intraocular, epidural, or intrathecal use due to the potential for serious adverse events that could be life threatening or lead to death. Please see full Prescribing Information for additional information on potential adverse events associated with these routes of administration. Additionally, KENALOG-10 is not for intramuscular use; and KENALOG-40 and KENALOG-80 are not for intradermal use.
From a BMS analysis of 14 published prospective randomized clinical trials or observational studies (N=1362), the most common adverse reactions (1-10%) in adults and pediatrics were: arthralgia (3.1%), infection (2.2%), headache (1.4%), and injection site reaction (1.1%).*
Please see full Prescribing Information for KENALOG-10 Injection.
Please see full Prescribing Information for KENALOG-40 and KENALOG-80 Injection.
*Data on File. TRIA001. Bristol-Myers Squibb Company, Princeton, NJ.
KENALOG Injection is not for use in neonates. Contains benzyl alcohol.
KENALOG is not for intravenous, intraocular, epidural, or intrathecal use due to the potential for serious adverse events that could be life threatening or lead to death. Please see full Prescribing Information for additional information on potential adverse events associated with these routes of administration. Additionally, KENALOG-10 is not for intramuscular use; and KENALOG-40 and KENALOG-80 are not for intradermal use.